Efficacy of Anti-Mullerian Hormone in Predicting the Levels of Sex Hormones and Pregnancy Outcomes in Patients with Polycystic Ovary Syndrome Undergoing IVF-ET

Our study aimed to explore the value of Anti-Mullerian hormone (AMH) level in sex hormone level and pregnancy outcome in patients with the polycystic ovarian syndrome (PCOS) who underwent Invitro fertilization-embryo transfer (IVF-ET). This study selected 200 patients with PCOS who took IVF-ET in our hospital from January 2016 to January 2020 as subjects. The study subjects were divided into group A (low-level group, n=90) and group B (high-level group, n=110) according to serum AMH levels; and group C (successful group, n= 88) and group D (failure group, n=112) according to whether they completed clinical pregnancy. These groups were used to compare the differences in sex hormone, pregnancy outcomes, and ROC curve analysis of serum AMH levels in the predictive value of IVF-ET clinical pregnancy in PCOS patients. Subjects in Group A showed significantly lower FSH, LH, and T levels (P<0.05) than Group B. Compared to patients in Group B, patients in Group A also showed significantly higher rate in implantation rate, high-quality embryo rate, biochemical pregnancy rate as well as clinical pregnancy rate (P<0.05), while the incidence of early miscarriage, pregnancy-induced hypertension, and gestational diabetes of patients in Group A is significantly lower (P<0.05). AMH level showed high specificity (77.52%) and sensitivity (81.46%) in predicting IVF-ET clinical pregnancy in PCOS patients. PCOS patients with lower AMH levels showed better sex hormone levels and clinical pregnancy outcomes in IVF-ET. Serum AMH level is valuable (of good value) in predicting IVF-ET clinical pregnancy in PCOS patients. In clinical practice, interventions can be taken in advance for patients with higher serum AMH levels to improve pregnancy outcomes.